IXC 2.86% 7.2¢ invex therapeutics ltd

Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-79

  1. 17,599 Posts.
    lightbulb Created with Sketch. 431
    This has been a very large set back and the market has reflected this .
    It will take a while to digest the ramifications.
    One thing that concerned me a little was the need for trial participants to have lumbar punctures and possibly recruitment reluctance however I thought the IIh dehabilating condition and discomfort could offset this .
    Didn’t they have consultants inputting into trial design ? And now we are going to have more consultants figuring out if now even viable .
    Wonder if some directors hang around now ?
    I think this could be a dead duck unfortunately now .
    Even if they go in another direction eg traumatic brain injury it could mean starting from square one .

    ( just my random thoughts)
 
watchlist Created with Sketch. Add IXC (ASX) to my watchlist
(20min delay)
Last
7.2¢
Change
0.002(2.86%)
Mkt cap ! $5.411M
Open High Low Value Volume
7.2¢ 7.2¢ 7.2¢ $1.701K 23.62K

Buyers (Bids)

No. Vol. Price($)
2 76375 7.2¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 5000 1
View Market Depth
Last trade - 15.42pm 13/09/2024 (20 minute delay) ?
IXC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.